XTL Biopharmaceuticals has shuttered the development program for XTL-2125 after it failed to demonstrate efficacy in a Phase I trial for hepatitis C. Viral load reductions proved negligible in comparison to a control group. A total of 56 volunteers were divided into eight groups, two of which received placebo.
- take a look at XTL's announcement on the closure
- here's the report from Globes on the trial failure
XTL licenses development rights to pain therapy. Report
XTL names Ron Bentsur CEO. Report